An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
Powder samples of the ABO3 perovskite manganites Pr0.6Sr0.4CrxMn1-xO3 (0.00≤x≤0.30) were synthesized using the sol-gel method. X-ray diffraction analyses showed that all the samples had a single-phase orthorhombic structure. By analyzing magnetic parameters on the basis of the O2p itinerant electron model, we found that there are two magnetic transition temperatures, TCM and TCP, corresponding to changes in the magnetic ordering for the Mn and Pr cations, respectively. The magnetic moments of Mn3+ and Cr3+ cations within the B sublattice show canted ferromagnetic coupling, and the magnetic moments of the Pr cations within the A sublattice also show canted ferromagnetic coupling. However, the total magnetic moment of the A sublattice shows antiferromagnetic coupling against that of the B sublattice. The assumption of the canted ferromagnetic coupling within the B sublattice was confirmed using magnetoresistance experimental results.
The study is to investigate the pharmacokinetics of S-1 capsule (tegafur, gimeracil and potassium oxonate capsule) in patients with advanced gastric cancer after single and multiple oral administration. Twelve patients with advanced gastric cancer were recruited to the study. The dose of S-1 for each patient was determined according to his/her body surface area (BSA). The dose for single administration was 60 mg every subject. The dose for multiple administration for one subject was as follows: 100 mg x d(-1) or 120 mg x d(-1), 28-days consecutive oral administration. The pharmacokinetic parameters of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil after single oral administration were as follows: (2,207 +/- 545), (220.0 +/- 68.2), (374.9 +/- 103.0), (110.5 +/- 100.8) and (831.1 +/- 199.9) ng x mL(-1) for Cmax; (11.8 +/- 3.8), (4.4 +/- 3.3), (7.8 +/- 5.1), (3.1 +/- 0.9) and (8.8 +/- 4.1) h for t1/2, respectively. After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively. The cumulative urine excretion percentage of tegafur, 5-fluorouracil, gimeracil and potassium oxonate in urine within 48 h were (4.2 +/- 2.8) %, (4.7 +/- 1.6) %, (18.5 +/- 6.0) % and (1.7 +/- 1.2) %, repectively, after single oral administration of S-1. The results exhibited that tegafur had some drug accumulation observed, and gimeracil, potassium oxonate, 5-fluorouracil and uracil had no drug accumulation observed.
Powder samples of the ferrites MxMn1-xFe2O4 (M = Zn, Mg, Al) were prepared using a chemical co-precipitation method. X-ray diffraction analysis showed that the three series of samples had a single-phase cubic spinel structure and that there was a decrease in the lattice parameters with increasing x. There were different dependences on the doping level x of the magnetic moments (μexp) for the three series of samples measured at 10 K. We found a non-monotonic behavior for μexp as a function x for the Zn doped samples with a maximum at x = 0.4, while μexp decreased monotonically with increasing x for the Mg and Al doped samples. On the basis of the O2p itinerant electron model, the magnetic moment direction of the Mn3+ cations is expected to be antiparallel to those of the Mn2+ and Fe cations in these samples. With this assumption, the curves of μexp versus x for the three series of samples were fitted using a quantum-mechanical potential barrier model earlier proposed by our group, and the cation distributions were obtained.
Nanomedicine engulfed by macrophages for targeted tumor therapy Siwen Li,1,* Song Feng,1,* Li Ding,1 Yuxi Liu,1 Qiuyun Zhu,1 Zhiyu Qian,2 Yueqing Gu1 1Department of Biomedical Engineering, China Pharmaceutical University, 2Department of Biomedical Engineering, School of Automation, Nanjing University of Aeronautics and Astronautics, Nanjing, Jiangsu, People’s Republic of China *These authors contributed equally to this work Abstract: Macrophages, exhibiting high intrinsic accumulation and infiltration into tumor tissues, are a novel drug vehicle for directional drug delivery. However, the low drug-loading (DL) capacity and the drug cytotoxicity to the cell vehicle have limited the application of macrophages in tumor therapy. In this study, different drugs involving small molecular and nanoparticle drugs were loaded into intrinsic macrophages to find a better way to overcome these limitations. Their DL capacity and cytotoxicity to the macrophages were first compared. Furthermore, their phagocytic ratio, dynamic distributions, and tumoricidal effects were also investigated. Results indicated that more lipid-soluble molecules and DL particles can be phagocytized by macrophages than hydrophilic ones. In addition, the N-succinyl-N'-octyl chitosan (SOC) DL particles showed low cytotoxicity to the macrophage itself, while the dynamic biodistribution of macrophages engulfed with different particles/small molecules showed similar profiles, mainly excreted from liver to intestine pathway. Furthermore, macrophages loaded with SOC–paclitaxel (PTX) particles exhibited greater therapeutic efficacies than those of macrophages directly carrying small molecular drugs such as doxorubicin and PTX. Interestingly, macrophages displayed stronger targeting ability to the tumor site hypersecreting chemokine in immunocompetent mice in comparison to the tumor site secreting low levels of chemokine in immunodeficiency mice. Finally, results demonstrated that macrophages carrying SOC–PTX are a promising pharmaceutical preparation for tumor-targeted therapy. Keywords: macrophage, drug-loading capacity, SOC–PTX, tumor-targeted therapy
Nanomaterials are a new option to successfully treat the multiresistant microorganisms.The as-prepared bismuth oxide with the optimal concentration exhibits stronger antibacterial abilities than others.Meanwhile, it exhibits well biocompatibility.In one word, the present approach can shed new light on designing of antibacterial material like bismuth oxide with promising applications in biological sciences.
A sensitive and specific liquid chromatographic-electrospray ionization (ESI) tandem ion trap mass spectrometric method has been developed for identification of bencycloquidium bromide (BCQB) and its metabolites in rat bile. Six healthy rats were administrated a single dose (3.0 mg kg −1 ) of BCQB by intraperitoneal (i.p.) injection. The bile were sampled from 0h to 24h and purified by using a C 18 solid-phase extraction (SPE) cartridge, then the purified bile samples were separated on a reversed-phase C 18 column using acetonitrile/40 mM ammonium acetate buffer (containing 0.1% formic acid) as mobile phase at gradient elution and detected by an on-line MS n detector. Identification and structural elucidation of the metabolites were performed by comparing the changes in molecular weight (Δ m) and full scan MS n spectra with those of the parent drug. Eight metabolites (such as hydroxylated and oxidized metabolites) and the parent drug were found in rat bile. Eight metabolites of BCQB were identified and hydroxylated metabolites were the major metabolites. The metabolic pathways of BCQB in vivo are proposed for the first time.
In the present study, a liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI- MS/MS) method was developed for the screening and the structural elucidation of the metabolites of ecabet bismuth in rat bile. Solid-phase extraction cartridges were used for sample pre-treatment and a gradient liquid chromatographic system composed of 10 mM ammonium acetate buffer and methanol was used for chromatographic separation on a Phenomenex Kromasil C(18) column. The triple quadrupole mass spectrometer was employed to thoroughly detect and acquire the detailed MS/MS spectra of ecabet and its metabolites. By comparing the chromatographic retention behaviors, as well as the changes in molecular weight and full-scan MS/MS spectra of the potential metabolites with those of the parent compound, two main metabolites were identified as glucuronide conjugate of carbonylated ecabet (7-oxo-ecabet) and glucuronide conjugate of ecabet. Both two metabolites have not been reported in the literatures. The metabolic pathways of ecabet in rat were also proposed in this paper.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)